Can Technology Fix American Health Care With 7investing Advisor Dana Abramovitz
Listen now
Description
America's health care system is a complex beast. It's costing us $4 trillion per year -- roughly $11,000 for every man, woman, and child in the country -- and that's nearly double the per capita spend of other developed nations. Even with the premium price tag, our health outcomes are still lagging many of those other countries. However, there is still cause for optimism. We've diagnoses several of our health care's symptoms, and higher-level changes are taking place to provide some much-needed improvements. And while we're all very excited about improving our country's overall health, is there also a way to benefit from massive overhaul as investors? To help us answer that question, we've looked to our own team for guidance! 7investing lead advisor Dana Abramovitz has dedicated her career to improving health care in America. From an undergrad in pharmacy to a PhD in biochemistry to an industry consultant who advised CEOs, she's seen the industry from all angles and understands its biggest pain points. In her conversation with 7investing founder and CEO Simon Erickson, Dana describes why value-based care, personalized medicines, and a transition in thinking about "patients" as "consumers" will all be vitally important in the upcoming changes to health care. The two allude several times to Dana's new 7investing special report entitled "Can Technology Fix American Health Care", which is now freely available by clicking on this link. Publicly-traded companies mentioned in this interview include Alphabet (Nasdaq: GOOGL) and Apple (Nasdaq: AAPL). 7investing's advisors or its guests may have positions in the companies mentioned. --- Send in a voice message: https://anchor.fm/7investing/message Support this podcast: https://anchor.fm/7investing/support
More Episodes
If you’ve ever travelled abroad or tried to send money across international borders, hidden fees and unfair exchange rates have no doubt been a massive and expensive headache. In this week’s episode of the 7investing podcast, Lead Advisors Luke Hallard & Krzysztof Piekarski sit down with...
Published 04/16/24
Published 04/16/24
ShockWave Medical (Nasdaq: SWAV), the innovative pioneer of intravascular lithotripsy, has received an all-cash acquisition offer from Johnson & Johnson (NYSE: JNJ) for $335 per share. In today's episode, 7investing advisors Luke Hallard and Simon Erickson discuss why we made ShockWave a...
Published 04/05/24